


Curriculum Vitae

| | | |
|-------------------------------------------|-----------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Name | Amit M. Oza |  |
| Current Position & Affiliation | Assistant Professor, Obstetrics and Gynaecology, University of Toronto, Canada | |
| Country | Canada | |

Educational Background

Degrees

1992 Dec MD, St. Bartholomew’s Hospital, University of London, United Kingdom

1983 Jun M.B., B.S. St. Bartholomew’s Hospital, University of London, United Kingdom

1980 Jun B.Sc. [First Class Honours], University of London, United Kingdom

Postgraduate, Research and Specialty Training

1993 Feb - 1993 May Clinical Research Fellow, Nederland’s Kanker Institut, Amsterdam, Netherlands

1992 Feb - 1993 Jun Clinical Research Fellow, Division of Medical Oncology & Hematology, Princess Margaret Hospital, Toronto, Canada

1989 Nov - 1992 Jan Clinical Research Fellow Honors, Senior Registrar, ICRF Department of Medical Oncology, St. Bartholomew’s Hospital Medical College, London, United Kingdom

1989 Nov - 1990 Dec Clinical Research Fellow, Imperial Cancer Research Fund, Tissue Antigen Laboratory, St. Bartholomew’s Hospital Medical College

1987 Aug - 1988 Oct Clinical Research Fellow/Honor Registrar, ICRF Department of Medical Oncology, St. Bartholomew’s Hospital Medical College, London, United Kingdom

1986 Aug - 1987 Jul Registrar, General Medicine Intensive Care, Whipps Cross Hospital, London, United Kingdom

1985 Aug - 1986 Jan Senior House Officer, Neurological Sciences Department, St. Bartholomew’s Hospital Medical College, London, United Kingdom

1985 Feb - 1986 Jul Resident Medical Office, Cardiology, National Heart Hospital, London, United Kingdom

1984 Aug - 1985 Jul House Surgeon, General Surgery & Orthopedics, Hackney Hospital, London, United Kingdom

1984 Aug - 1985 Jul Senior House Officer, Radiotherapy & Oncology, Chest Medicine, Endocrinology, & Clinical Pharmacology, Radcliffe Infirmary & Churchill Hospital, Oxford, United Kingdom

1983 Aug - 1984 Jan House Physician, Medical Oncology, General Medicine and Rheumatology, St. Bartholomew's Hospital Medical College, London, United Kingdom
Amit M. OZA

Page 2 of 62 Generated by Web CV - 2021 Jan 6 **CONFIDENTIAL DOCUMENT**

Qualifications, Certifications and Licenses

1998 May FRCP(UK), Royal College of Physicians, United Kingdom

1993 Nov FRCPC, Internal Medicine, Royal College of Physicians and Surgeons of Canada, Canada

1991 Sep Accreditation, Medical Oncology, Royal College of Physicians, United Kingdom

1986 Jul M.R.C.P. (U.K.), Royal College of Physicians, United Kingdom

Professional Experience

Current Appointments

2018 - present Senior Scientist, Princess Margaret Cancer Research Institute, Toronto, Ontario, Canada

2016 Jun - present Head, Division of Medical Oncology and Hematology for UHN and Sinai Health System, Head, The Division of Medical Oncology and Hematology for UHN and Sinai Health System, Medicine, Princess Margaret Hospital, Toronto, Ontario, Canada

2014 - present Chair, Investigational Drug Steering Committee, NCI, Bethesda, District of Columbia, United States

2013 - present Director, Clinical Research, DMOH, Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

2009 - present Senior Staff Physician and Consultant Medical Oncologist, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

2008 - present Professor of Medicine, Medicine, Faculty of, University of Toronto, Canada

2008 - present Professor, Obstetrics and Gynecology, Obstetrics and Gynecology, Medicine, Faculty of, University of Toronto, Toronto, Ontario, Canada

2007 - present Fields Institute Fellow, Centre for Mathematical Medicine, The Fields Institute, Canada

2000 - present Assistant Professor, Obstetrics and Gynaecology, University of Toronto, Canada

2000 - present Scientist, Division of Cancer, Informatics, Ontario Cancer Institute, Canada

1993 - present Consultant, Division of Medical Oncology & Hematology, Mount Sinai Hospital, Canada

2020 Jun 1 - 2022 May 31 Chair, Gynecologic Cancer InterGroup (GCIG)

2016 Jun Bergsagel Chair, Medical Oncology and Hematology for UHN and Sinai Health System, Medicine, Princess Margaret Hospital, Toronto, Ontario, Canada

2015 Faculty, GCIG Consensus Meetings - Ovarian Cancer

2012 Jul 1 Clinician Scientist, Medical Oncology, Medicine, Faculty of, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

2011 Jan Chief Executive Officer (CEO), Ozmosis, Toronto, Ontario, Canada A *Social Enterprise, Clinical Trials Management Company*

2010 Faculty, GCIG Consensus Meetings - Ovarian Cancer

2004 Faculty, GCIG Consensus Meetings - Ovarian Cancer

Previous Appointments

HOSPITAL

2015 Jul - 2016 Jun Acting Head, Division of Medical Oncology and Hematology for UHN and Sinai Health System, Head of The Division of Medical Oncology and Hematology for UHN and Sinai Health System, Medicine, Princess Margaret Hospital, Toronto, Ontario, Canada

2014 May - 2014 Aug Acting Head, Medical Oncology and Hematology Program, Medical Oncology and Hematology, Medicine, Princess Margaret Hospital, Toronto, Ontario, Canada

2009 - 2017 Medical Director, Clinical Cancer Research Unit, Princess Margaret Cancer Centre, Toronto, Ontario, Canada

2006 Jul - 2006 Dec Acting Head, Medical Oncology and Hematology Program, Princess Margaret Hospital, Canada

2003 - 2005 Deputy Head, Division of Medical Oncology & Hematology, Princess Margaret Hospital, Canada

RESEARCH

2018 Dec 1 - 2020 May 31 Chair-Elect, Gynecologic Cancer InterGroup (GCIG)

2012 - 2019 Executive Director, Gynecologic Cancer InterGroup, Ontario, Canada

UNIVERSITY

2005 - 2009 Director, Centre for Mathematical Medicine, Centre for Mathematical Medicine, The Fields Institute, Toronto, Ontario, Canada

2005 Co-Founder, Centre for Mathematical Medicine, The Fields Institute, Toronto, Ontario, Canada

UNIVERSITY - RANK

2002 - 2008 Associate Professor, Medicine, University of Toronto, Canada

1993 - 2002 Assistant Professor, Medicine, University of Toronto, Canada

1989 Nov - 1992 Jan Lecturer, ICRF Department of Medical Oncology, St. Bartholomew's Hospital, London, United Kingdom

Professional Organizations

American Association of Cancer Research
American Society of Clinical Oncology
Association of Cancer Physicians of UK
British Association of Cancer Research
British Oncological Association
Canadian Association of Medical Oncologists
European Society of Medical Oncology
International Gynecologic Cancer Society
Society of Gynecologic Oncologists of Canada

Main Scientific Publications

1. Coleman RL, **Oza AM**, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clapp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA, ARIEL3 investigators. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2017 Oct 28;390(10106):1949-1961. Impact Factor 44.002. **Coauthor or Collaborator**.
2. Lheureux S, Bruce JP, Burnier JV, Karakasis K, Shaw PA, Clarke BA, Yang SY, Quevedo R, Li T, Dowar M, Bowering V, Pugh TJ, **Oza AM**. Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition. *J Clin Oncol*. 2017 Apr 10;35(11):1240-1249. Impact Factor 20.982. **Senior Responsible Author**.
3. Mirza MR, Monk BJ, Herrstedt J, **Oza AM**, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balsler JP, Agarwal S, Matulonis UA, ENGOT-OV16/NOVA Investigators. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. *N Engl J Med*. 2016 Dec 1;375(22):2154-2164. **Coauthor or Collaborator**.

4. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, **Oza AM**, ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. *N Engl J Med*. 2011 Dec 29;365(26):2484-96. Erratum: 366:284, 2012. Impact Factor 53.298. **Senior Responsible Author.** *First new ovarian cancer drug in 15 years to improve outcome, delaying disease for two months overall. As co-lead PI, the trial enrolled >1500 women with ovarian cancer at 263 centres across the world, 20 in Canada. When added to chemotherapy treatment, avastin improves PFS; benefits to PFS and OS were greater among those at high risk for disease progression.*

5. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, **Oza AM**. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer. A phase 2, multicentre, open-label, non-randomised study. *Lancet Oncol*. 2011 Jul;12:852-861. Impact Factor 18.73. **Principal Author.** *First study suggesting the small molecule potent oral poly(ADP-ribose) polymerase (PARP) inhibitor olaparib is a promising treatment for women with high grade serous ovarian cancer without germline BRCA1/2 mutations. 65 women with high-grade serous and/or undifferentiated and/or known BRCA-mutated ovarian and/or fallopian-tube or peritoneum cancer were enrolled onto study in 13 months. Objective response rates reported here were similar to those reported for other ovarian cancer treatments including pegylated liposomal doxorubicin and topotecan.*